

# Daniel Eiger

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7123441/publications.pdf>

Version: 2024-02-01

18  
papers

365  
citations

1039880

9  
h-index

996849

15  
g-index

18  
all docs

18  
docs citations

18  
times ranked

554  
citing authors

#	ARTICLE	IF	CITATIONS
1	BERENICE Final Analysis: Cardiac Safety Study of Neoadjuvant Pertuzumab, Trastuzumab, and Chemotherapy Followed by Adjuvant Pertuzumab and Trastuzumab in HER2-Positive Early Breast Cancer. <i>Cancers</i> , 2022, 14, 2596.	1.7	8
2	Atezolizumab With Neoadjuvant Anti-Human Epidermal Growth Factor Receptor 2 Therapy and Chemotherapy in Human Epidermal Growth Factor Receptor 2-Positive Early Breast Cancer: Primary Results of the Randomized Phase III IMpassion050 Trial. <i>Journal of Clinical Oncology</i> , 2022, 40, 2946-2956.	0.8	46
3	The Exciting New Field of HER2-Low Breast Cancer Treatment. <i>Cancers</i> , 2021, 13, 1015.	1.7	83
4	Cardiotoxicity of immune checkpoint inhibitors: A systematic review and meta-analysis of randomised clinical trials. <i>European Journal of Cancer</i> , 2021, 148, 76-91.	1.3	33
5	Cardiac safety of dual anti-HER2 blockade with pertuzumab plus trastuzumab (P+T) in the APHINITY trial. <i>Journal of Clinical Oncology</i> , 2021, 39, 510-510.	0.8	3
6	Clinical outcomes of platinum-based chemotherapy in patients with advanced breast cancer: An 11-year single institutional experience. <i>Breast</i> , 2021, 57, 86-94.	0.9	6
7	Clinical Implications of Body Mass Index in Metastatic Breast Cancer Patients Treated With Abemaciclib and Endocrine Therapy. <i>Journal of the National Cancer Institute</i> , 2021, 113, 462-470.	3.0	20
8	Lessons learned at SABCS 2019 and to-dos from immunotherapy in breast cancer. <i>ESMO Open</i> , 2020, 5, e000688.	2.0	0
9	Long-term cardiac outcomes of patients with HER2-positive breast cancer treated in the adjuvant lapatinib and/or trastuzumab Treatment Optimization Trial. <i>British Journal of Cancer</i> , 2020, 122, 1453-1460.	2.9	22
10	Computed tomography-based analyses of baseline body composition parameters and changes in breast cancer patients under treatment with CDK 4/6 inhibitors. <i>Breast Cancer Research and Treatment</i> , 2020, 181, 199-209.	1.1	19
11	The impact of cyclin-dependent kinase 4 and 6 inhibitors (CDK4/6i) on the incidence of alopecia in patients with metastatic breast cancer (BC). <i>Acta Oncologica</i> , 2020, 59, 723-725.	0.8	7
12	Cardiotoxicity of trastuzumab given for 12 months compared to shorter treatment periods: a systematic review and meta-analysis of six clinical trials. <i>ESMO Open</i> , 2020, 5, e000659.	2.0	6
13	Pertuzumab in HER2-positive early breast cancer: current use and perspectives. <i>Future Oncology</i> , 2019, 15, 1823-1843.	1.1	14
14	Biomarkers of response and resistance to PI3K inhibitors in estrogen receptor-positive breast cancer patients and combination therapies involving PI3K inhibitors. <i>Annals of Oncology</i> , 2019, 30, x27-x42.	0.6	63
15	Complete lymphadenectomy following positive sentinel lymph node biopsy in cutaneous melanoma: a critical review. <i>Anais Brasileiros De Dermatologia</i> , 2018, 93, 553-558.	0.5	8
16	Continuous palliative sedation for patients with advanced cancer at a tertiary care cancer center. <i>BMC Palliative Care</i> , 2018, 17, 13.	0.8	27
17	Experience with palliative sedation (PS) in an inpatient oncology setting. <i>Journal of Clinical Oncology</i> , 2016, 34, e21503-e21503.	0.8	0
18	Experience with palliative sedation (PS) in an inpatient oncology setting. <i>Journal of Clinical Oncology</i> , 2016, 34, 63-63.	0.8	0